In vivo antigen delivery by aSalmonella typhimurium type III secretion system for therapeutic cancer vaccines
Open Access
- 3 July 2006
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 116 (7) , 1946-1954
- https://doi.org/10.1172/jci28045
Abstract
Bacterial vectors may offer many advantages over other antigen delivery systems for cancer vaccines. We engineered a Salmonella typhimuriumvaccine strain to deliver the NY-ESO-1 tumor antigen (S. typhimurium–NY-ESO-1) through a type III protein secretion system. The S. typhimurium–NY-ESO-1 construct elicited NY-ESO-1–specific CD8+ and CD4+ T cells from peripheral blood lymphocytes ofcancer patients in vitro. Oral administration of S. typhimurium–NY-ESO-1 to mice resulted in the regression of established NY-ESO-1–expressing tumors. Intratumoral inoculation of S. typhimurium–NY-ESO-1 to NY-ESO-1–negative tumors resulted in delivery of antigen in vivo and led to tumor regression in the presence of preexisting NY-ESO-1–specific CD8+ T cells. Specific T cell responses against at least 2 unrelated tumor antigens not contained in the vaccine were observed, demonstrating epitope spreading. We propose that antigen delivery through the S. typhimuriumtype III secretion system is a promising novel strategy for cancer vaccine development.Keywords
This publication has 50 references indexed in Scilit:
- Toll-Like Receptor 8-Mediated Reversal of CD4 + Regulatory T Cell FunctionScience, 2005
- Determination of Cellularly Processed HLA-A2402-Restricted Novel CTL Epitopes Derived from Two Cancer Germ Line Genes, MAGE-A4 and SAGEClinical Cancer Research, 2005
- Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumor CellsCancer Research, 2005
- Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigenThe Journal of Experimental Medicine, 2005
- Toll-like receptor control of the adaptive immune responsesNature Immunology, 2004
- International Meeting on Cancer VaccinesCancer Research, 2004
- Antigen‐specific immunotherapy and cancer vaccinesInternational Journal of Cancer, 2003
- HER2 peptide-specific CD8+ T cells are proportionally detectable long after multiple DNA vaccinationsGene Therapy, 2002
- Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissuesInternational Journal of Cancer, 2001
- Efficient selection for high-expression transfectants with a novel eukaryotic vectorGene, 1991